Atrial Fibrillation Pipeline Outlook Report 2025: Key 10+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight's, "Atrial Fibrillation Pipeline Insight, 2025" report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Atrial Fibrillation pipeline landscape. It covers the Atrial Fibrillation pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Atrial Fibrillation pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Atrial Fibrillation Treatment Landscape. Click here to read more @ Atrial Fibrillation Pipeline Outlook [https://www.delveinsight.com/sample-request/atrial-fibrillation-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Atrial Fibrillation Pipeline Report

* In July 2025, Biosense Webster Inc . announced a STELLAR study is a pivotal, prospective, multicenter, single-arm, clinical evaluation of the Multi-Electrode RF Balloon catheter. The study will evaluate the safety and effectiveness of the Multi-Electrode RF Balloon catheter used for ablation in patients with paroxysmal atrial fibrillation (PAF).
* In July 2025, Medtronic Cardiac Rhythm and Heart Failure conducted a study is to demonstrate the efficiency on AT / AF prevention and termination of a new algorithm contained in the Medtronic AT500 Antitachycardia device in patients with conventional pacemaker indications.
* DelveInsight's Atrial Fibrillation pipeline report depicts a robust space with 10+ active players working to develop 12+ pipeline therapies for Atrial Fibrillation treatment.
* The leading Atrial Fibrillation Companies such as Thryv Therapeutics Inc., Janssen Research & Development LLC, HUYABIO International LLC., Milestone Pharmaceuticals Inc., Anthos Therapeutics Inc., Bayer and others.
* Promising Atrial Fibrillation Pipeline Therapies such as Anticoagulant Oral, SB424323, Dapagliflozin, Etripamil, Dronedarone, Milvexian, Apixaban, OMT-28 and others.

Stay informed about the cutting-edge advancements in Atrial Fibrillation Treatments. Download for updates and be a part of the revolution in Cardiovascular Diseases Care @ Atrial Fibrillation Clinical Trials Assessment [https://www.delveinsight.com/sample-request/atrial-fibrillation-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Atrial Fibrillation Emerging Drugs Profile

* Abelacimab: Anthos Therapeutics, Inc.

Abelacimab is a novel, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the activated form (Factor XIa). This mimics natural Factor XI deficiency, which is associated with protection from thromboembolic disease. As a fully human monoclonal antibody, abelacimab is not metabolized via the cytochrome P450 system or as a substrate for P-glycoprotein, meaning the risk for drug-drug interactions is very unlikely. There is also no need to adjust the dose based on age or renal/hepatic status and it can be safely co-administered with antiplatelet agents. Abelacimab is currently being evaluated in several ongoing Phase III clinical trials for patients at risk of dangerous arterial and venous clots, including those with atrial fibrillation and cancer associated thrombosis. In patients with atrial fibrillation, abelacimab is planned to be dosed subcutaneously once-monthly with an autoinjector to maintain near-complete inhibition in a chronic setting. It is also planned to be administered via an initial intravenous (IV) infusion for acute indications requiring immediate onset of action and then followed by subsequent monthly subcutaneous administration. Currently, the drug is in Phase III stage of its development for the treatment of Atrial Fibrillation.

* Etripamil: Milestone Pharmaceuticals Inc.

Etripamil is a fast-acting, intranasal calcium channel blocker developed for the acute management of paroxysmal supraventricular tachycardia (PSVT) and atrial fibrillation with rapid ventricular rate (AFib-RVR). Designed for self-administration, it is delivered via a nasal spray, allowing for quick absorption through the nasal mucosa, with onset of action typically within 10 minutes. Etripamil acts rapidly to control heart rate by blocking calcium influx into cardiac cells, helping to slow conduction through the atrioventricular (AV) node. Its short duration of action may reduce the risk of long-term side effects commonly associated with continuous use of traditional antiarrhythmic medications, making it a convenient and potentially safer option for managing sudden AFib episodes. Currently, the drug is in Phase II stage of its development for the treatment of Atrial Fibrillation.

* THRV-1268: Thryv Therapeutics, Inc.

THRV-1268 is a novel and potent inhibitor of the Serum Glucocorticoid Kinase 1 (SGK1). SGK1 is a PI3-kinase-dependent kinase with its expression and activation regulated by several metabolic signaling pathways that are crucial in cardiometabolic diseases. Thryv Therapeutic's first SGK1 inhibitor, LQT-1213, repeatedly demonstrated reductions in QTc interval in pre-clinical studies and in patients with the genetic and acquired Long QT Syndrome. SGK1 has been implicated in various pathological conditions, including QTc prolongation, arrhythmias, fibrosis, and heart failure. SGK1 dysfunction is also linked to cardiometabolic stressors such as obesity and hypertension, which are common comorbidities in heart failure. Genetic and pharmacological inhibition of SGK1 has been demonstrated to have a protective effect in a mouse model of obesity-related atrial fibrillation. In several preclinical models of heart failure, THRV-1268 mitigated the development of heart failure and fibrosis, and reduced heart failure biomarkers associated with adverse changes in hemodynamic and functional cardiovascular outputs. These findings demonstrate the potential of SGK1 inhibition in addressing the pathogenesis of heart failure and related cardiometabolic conditions, including atrial fibrillation. Currently, the drug is in Phase I stage of its development for the treatment of Atrial Fibrillation.

The Atrial Fibrillation Pipeline report provides insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Atrial Fibrillation with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Atrial Fibrillation Treatment.
* Atrial Fibrillation Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Atrial Fibrillation Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Atrial Fibrillation market.

Get a detailed analysis of the latest innovations in the Atrial Fibrillation pipeline. Explore DelveInsight's expert-driven report today! @ Atrial Fibrillation Unmet Needs [https://www.delveinsight.com/sample-request/atrial-fibrillation-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Atrial Fibrillation Companies

Thryv Therapeutics Inc., Janssen Research & Development LLC, HUYABIO International LLC., Milestone Pharmaceuticals Inc., Anthos Therapeutics Inc., Bayer and others.

Atrial Fibrillation pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical

Atrial Fibrillation Products have been categorized under various Molecule types such as

* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy

Discover the latest advancements in Atrial Fibrillation Treatment by visiting our website. Stay informed about how we're transforming the future of Cardiovascular Diseases @ Atrial Fibrillation Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/atrial-fibrillation-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Atrial Fibrillation Pipeline Report

* Coverage- Global
* Atrial Fibrillation Companies- Thryv Therapeutics Inc., Janssen Research & Development LLC, HUYABIO International LLC., Milestone Pharmaceuticals Inc., Anthos Therapeutics Inc., Bayer and others.
* Atrial Fibrillation Pipeline Therapies- Anticoagulant Oral, SB424323, Dapagliflozin, Etripamil, Dronedarone, Milvexian, Apixaban, OMT-28 and others.
* Atrial Fibrillation Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Atrial Fibrillation Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Atrial Fibrillation Pipeline on our website @ Atrial Fibrillation Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/atrial-fibrillation-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Atrial Fibrillation: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Atrial Fibrillation- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Abelacimab: Anthos Therapeutics, Inc.
* Mid Stage Products (Phase II)
* Etripamil: Milestone Pharmaceuticals Inc
* Early Stage Products (Phase I)
* THRV-1268: Thryv Therapeutics, Inc.
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Inactive Products
* Atrial Fibrillation Key Companies
* Atrial Fibrillation Key Products
* Atrial Fibrillation- Unmet Needs
* Atrial Fibrillation- Market Drivers and Barriers
* Atrial Fibrillation- Future Perspectives and Conclusion
* Atrial Fibrillation Analyst Views
* Atrial Fibrillation Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=atrial-fibrillation-pipeline-outlook-report-2025-key-10-companies-and-breakthrough-therapies-shaping-the-future-landscape]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/atrial-fibrillation-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.